Tilray Inc (NASDAQ: TLRY) announced this morning that it has successfully imported medical cannabis from Canada to the United States. The cannabis was imported in support of a clinical trial related to that of breast cancer research.
Specifically, the study is researching the impact that medical cannabis has on individuals that have breast cancer while also suffering from taxane-induced peripheral neuropathy (TIPN). Patients that have TIPN are typically not able to utilize chemotherapy to treat breast cancer to the same extent that those without the disorder are.
Within the study, a randomized group of patients suffering from TIPN will be given a twice daily dosage of active cannabinoids in the form of THC and CBD for eight weeks, while a control group will be given a placebo. It is unclear as to what form of delivery will be used for the cannabinoids within the study.
We’re excited to support this groundbreaking, first-of-its-kind trial seeking to find a new treatment option for TIPN. Tilray is committed to advancing cannabis research through its support of clinical trials around the world as we continue to enhance our understanding of the potential benefits of medical cannabis.Philippe Lucas, Tilray’s Vice President of Global Patient Research and Access
There are currently no effective treatments for TIPN on the markets, a disorder which effects approximately 67% of women underoing breast cancer treatment. However, early studies conducted on mice with medical cannabis provided positive results in the treatment of TIPN. The research that Tilray is involved within is the first human trial of utilizing medical cannabis to treat the disorder.
Tilray closed yesterday’s session at $22.63 on the Nasdaq.
Information for this briefing was found via Sedar and Tilray. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.